“showed a trend”

At the genus level, both groups showed a trend toward decreased abundance ( Figure 7 A; Test: p = 0.059 and Comparator: p = 0.051).

CVST response time showed a trend toward improvement over the course of the study ( p = 0.059), but a learning effect cannot be excluded here.

In addition, the absence of residual urine output was significantly associated with higher sleep disturbance scores ( p = 0.002), whereas the association with fatigue showed a trend toward statistical significance ( p = 0.059).

Older age was also independently associated with mortality (OR 1.07 per year, 95% CI 1.02–1.12; p = 0.003), while ASA score showed a trend that did not reach significance (OR 1.90, 95% CI 0.97–3.71; p = 0.059).

Kaplan–Meier curves showed a trend of significance regarding the association of miR-487b or miR-410 expression with overall survival ( P =0.059) and disease-free survival ( P =0.067) ( Supplementary Figure 1 ).

PF eyes in this study showed a trend toward a higher rate ( p = 0.059) of open revision.

In the case of detour latencies, the CI also showed a trend-like interaction with the number of closed door trials before the first open door trial (LR test: χ 2 (2) = 5.668; p = 0.059).

StructureIndex showed a trend toward a positive association ( p = 0.059).

Age effects regarding psychometric measures were not significant in the SAD, SP or HC groups ( p s > .11) but younger participants with SAD showed a trend towards higher self‐reported phobic fears (Mdn = 66) compared to older participants with SAD (Mdn = 52), W = 454, p = .059, and the same pattern emerged in participants with SP (younger: Mdn = 49; older: Mdn = 34.5, t (38.7) = 1.86, p = .070).

The Ara content showed a trend to decrease upon enzyme addition ( p = 0.059) from 0.3% ( w / w ) in WC to 0.2% ( w / w ) in WE.

Compared to younger subjects, older subjects reported less Impaired Control and Cognition and also showed a trend for more Blissful State ( p = 0.059).

The comparison between both groups showed a trend towards better DC rate in the “matched therapy group” ( p = 5.9 × 10 −2 ).

2 B) with regard to WT1 IgG Ab level in serous OC whereas patients with nonserous subtypes showed a trend to a poor clinical outcome correlated with high-WT1 IgG Ab level for PFS ( P = 0.059, Fig. 2 C).

The linear model for peak V o 2 accounts for >50% of the observed variability and showed a trend for peak V o 2 to be lower in women ( P =0.059) and a significant decrease of peak V o 2 with advancing age ( P =0.001) and increasing WBC ( P =0.026).

The individual fluid versus neuroimaging tau biomarker models did not differ from each other (plasma p-tau217 versus tau-PET MTL , P = 0.322; plasma p-tau217 versus tau-PET NEO , P = 0.750), while the performance of tau-PET MTL showed a trend toward better performance than tau-PET NEO ( P = 0.059).

The root extracts showed a trend toward increasing CASP9 expression ( p = 0.059), but this did not reach statistical significance, meaning that while there might be a potential effect, the data do not provide strong enough evidence to confirm a reliable upregulation at the tested doses.

For an unfavorable outcome (mRS 5–6 after 90 days), a higher NIHSS on admission showed a trend for unfavorable outcomes (OR 1.04, CI 1.00–1.085, p = 0.0591) (see Table 2 ).

In LN18 cells 213 Bi-anti-EGFR-MAb treatment induced also an increase, which showed a trend towards statistical significance (p = 0.0591): analysis of cell culture medium revealed a LDH activity of 31.1 ± 5.4 ng/ml and 46.6 ± 7,3 ng/ml for controls and 213 Bi-anti-EGFR-MAb treated cells, respectively.

The group treated with ZnO:9Ag showed a trend towards reduced collagen deposition compared to that in the group treated with the ZnO nanocrystals ( p = 0.0591). 3.4.

Baseline mNAPSI showed a trend toward positive association with PASDAS Good Responses (OR (95% CI): 1.6 (1.0 to 2.5), p=0.0592), whereas psoriasis-affected BSA was not associated with PASDAS Good Responses (p=0.2926) ( figure 1 and online supplemental table 1 ).

RP slope and PANSS General symptoms scores showed a trend towards a significant negative correlation (τ = − 0.49; p = 0.0593).

Calcium accumulation in channelled constructs showed a trend towards a significant increase, as compared to solid constructs, at 4 weeks post-implantation (4.37±0.61 vs. 3.27±0.33%ww, p = 0.0593), with this difference becoming significant at 8 weeks post-implantation (7.97±1.15 vs. 5.12±0.53%ww, p <0.0001).

Although patients with higher free AIM concentrations on day 1 showed a trend toward improved 30-day survival (p = 0.0595), statistical significance was not reached until day 8.

After adjusting the covariates, age, sex, and comorbidities in the multivariate analysis, the duration of treatment was a significant factor that increased the risk of developing renal events (> 1 to ≤ 3 years, risk ratio [RR] 1.2, 95% CI 1.12–1.54; P = 0.0007; > 3 to ≤ 5 years, RR: 1.38, 95% CI 1.04–1.84; P = 0.0254) while consistency of use was not statistically significant but showed a trend towards increasing the risk of developing renal events (RR: 1.24, 95% CI 0.99–1.55; P = 0.0595) (Table 3 ).

A recent randomized controlled trial of 36 TA patients in remission assigned to placebo or the novel interleukin-6 receptor antagonist tocilizumab showed a trend toward increased time to relapse without reaching significance (p = 0.0596) ( 7 ).